Emma's current research focuses on the profiling of the genomic regulatory landscape of discrete cell populations derived from post-mortem brain samples. This work holds significant potential in providing valuable understanding of both neurodegeneration and neuropsychiatric disorders at the cellular level. Based on this research they are developing blood-based biomarkers for neurodegenerative disorders including Alzheimer’s Disease and Motor Neuron Disease. Another aspect of Emma's work involves developing new methods such as epigenomic tools based on the CRISPR-cas9 system to understand the role epigenetics play in brain disorders such as Alzheimer’s disease.